Vaccines Against Primary Progressive Aphasia (PPA)

Primary Progressive Aphasia (PPA) is a neurodegenerative disease whose primary manifestation is the degradation or even loss of language function. Vaccines are a cost-effective strategy for disease. Creative Biolabs enjoys a high reputation in the field of vaccines. We also have extensive experience in the development of vaccines for neurodegenerative diseases. If you are also working in this area, we will be your best partner.

Primary Progressive Aphasia (PPA)

Primary progressive aphasia (PPA) is a neglected and underestimated neurodegenerative disease in which the language ability of a patient with this disease is slowly and gradually weakened or even lost. In addition to language function disorders, other possible accompanying symptoms are associated with damaged areas in the left hemisphere of the patient's brain. According to the classic classical Mesulam criteria, PPA has three variants: non-fluent type progressive non-fluent aphasia (PNFA), fluent type semantic dementia (SD), and logopenic progressive aphasia (LPA). Primary progressive aphasias have some overlap with Alzheimer's disease in clinical features and pathology, but it differs from AD in that patients with PPA generally still have the ability to take care of themselves, while in AD patients, the decline in expression and language function is only one of the manifestations of neurodegenerative.

Primary progressive aphasia (PPA) – Creative Biolabs

Development of Vaccines against PPA

There are not many studies on PPA, nor the specific drugs for this disease. Sometimes, the prescription for PPA patients is the same as that for AD patients. In addition, speech therapy is also a commonly used means of improving PPA, which can help patients overcome the inconvenience caused by the disease. In some clinical trials, for example, a small randomized trial conducted by Reed found that dopamine antagonists did not provide benign effects. Another tau-targeted vaccine designed for patients with non-fluent variant of PPA showed good safety in stage I clinical trials. The vaccine has potential in preventing the accumulation of tau in neurons in patients with neurodegenerative diseases, and the antibodies to this vaccine also have therapeutic potential for tauopathies.

Primary progressive aphasia is a relatively rare disease. Not only will patients gradually lose their language skills, but their families will suffer from depression and helplessness. As a company with a mission and career in human health and happiness, Creative Biolabs has always been arming itself with a cutting-edge research team and multiple advanced technology platforms and is constantly committed to developing a weapon-vaccines to fight against disease. Through enjoyable cooperation with global vaccine researchers, we have jointly promoted the development of human health. So if you have any needs in this area, let's start this great and enjoyable collaboration together!


Our services are for research use only. We do not provide services directly to individuals.


Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.

CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-466-5530
Fax: 1-631-207-8356
Email: Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
Tel: 44-207-097-1828 Email:


Follow us on

facebook   twitter   linked   blog

Shopping Basket